Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.40 |
| ▸ | TDO2 | P48775 | 2/20 | 0.40 |
| ▸ | KCNMA1 | Q12791 | 2/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7546534 | 0.81 | CA1 (0.48) | IDO1TDO2SLC6A4TRPA1AR | |
| SCHEMBL10292484 | 0.79 | TRPA1 (0.56) | TRPA1ARMEN1KMT2A | |
| SCHEMBL5607173 | 0.79 | ALDH1A1 (0.56) | IDO1TDO2SLC6A4TRPA1 | |
| SCHEMBL5607617 | 0.77 | IDO1 (0.43) | IDO1TDO2KCNMA1SLC6A4 | |
| SCHEMBL18319346 | 0.75 | HTR2A (0.50) | SLC6A4MEN1KMT2A | |
| SCHEMBL30490056 | 0.75 | HTR2A (0.50) | SLC6A4MEN1KMT2A | |
| SCHEMBL24832377 | 0.74 | SMN1; SMN2 (0.47) | SLC6A4ARMEN1KMT2A | |
| SCHEMBL5607414 | 0.73 | AR (0.46) | TRPA1ARMEN1KMT2A | |
| SCHEMBL7006874 | 0.73 | TTR (0.61) | TRPA1AR | |
| SCHEMBL29355313 | 0.73 | TTR (0.61) | TRPA1AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1838300-A2 | 2-(2 OR 4-SUBSTITUTED ARYLOXY)-PHENOL DERIVATIVES AS ANTIBACTERIAL AGENTS | Emergent Product Development Gaithersburg Inc. (US) | 2007-10-03 | — | — | EP | claimed |
| US-20060211697-A1 | 2-(2 Or 4-substituted aryloxy)-phenol derivatives as antibacterial agents | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG, INC. | 2006-09-21 | — | — | US | claimed |
| WO-2006071471-A2 | 2-(2 OR 4-SUBSTITUTED ARYLOXY)-PHENOL DERIVATIVES AS ANTIBACTERIAL AGENTS | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. (US) | 2006-07-06 | — | — | WO | claimed |
| EP-1838300-A2 | 2-(2 OR 4-SUBSTITUTED ARYLOXY)-PHENOL DERIVATIVES AS ANTIBACTERIAL AGENTS | Emergent Product Development Gaithersburg Inc. (US) | 2007-10-03 | — | — | EP | disclosed |
| US-20060211697-A1 | 2-(2 Or 4-substituted aryloxy)-phenol derivatives as antibacterial agents | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG, INC. | 2006-09-21 | — | — | US | disclosed |
| WO-2006071471-A2 | 2-(2 OR 4-SUBSTITUTED ARYLOXY)-PHENOL DERIVATIVES AS ANTIBACTERIAL AGENTS | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. (US) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211697-A1 | 2-(2 Or 4-substituted aryloxy)-phenol derivatives as antibacterial agents | TYR, NFE2L2, CYP1A1 | IDO1 1513/4885TDO2 115/4885KCNMA1 4194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.